Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling

Daniel R. Richardson, MD MA, Allison H. Oakes, Gary Rathsmill, Crystal Reinhart, Bernadette O'Donoghue, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 717.

https://doi.org/10.1182/blood-2018-99-116669

Published: 2018

Journal Articles

Quantifying Patient Preferences for Treatment Outcomes in AML: A Discrete-Choice Experiment

Daniel R. Richardson, MD MA, Jaein Seo, PharmD, B. Douglas Smith, MD, Elihu H. Estey, MD, Bernadette O'Donoghue, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 718.

https://doi.org/10.1182/blood-2018-99-113071

Published: 2018

Journal Articles

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Norah Crossnohere, MPH, Daniel R. Richardson, MD MA, B. Douglas Smith, MD, Crystal Reinhart, Bernadette O'Donoghue, Susan Love, MD MBA, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2018-99-116931

Published: 2018

Journal Articles

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Daniel R Richardson, MD, Ying Huang, MA, MS, Patrick Elder, MS, Joanna Newlin, LISW, Cyndi Kirkendall, LISW, Steven M Devine, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Craig C Hofmeister, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Heather L McGinty, PhD, Sam Penza, MD, Sumithra Vasu, MBBS, Basem M William, MD, Ashley E Rosko, MD

Blood (2016) 128 (22): 1241.

https://doi.org/10.1182/blood.V128.22.1241.1241

Published: 2016

Journal Articles

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Daniel R Richardson, MD, Qiuhong Zhao, MS, Rhonda Kitzler, MS, Patrick Elder, MS, Gerard Lozanski, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Sam Penza, MD, Sumithra Vasu, MBBS, Steven M Devine, MD

Blood (2016) 128 (22): 4598.

https://doi.org/10.1182/blood.V128.22.4598.4598

Published: 2016

NARROW

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling

Quantifying Patient Preferences for Treatment Outcomes in AML: A Discrete-Choice Experiment

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Email alerts

ASH Publications

American Society of Hematology

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling

Quantifying Patient Preferences for Treatment Outcomes in AML: A Discrete-Choice Experiment

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only